Regeneron shares rose 13.3%: Dupixent profits drive earnings surge

Regeneron shares rose 13.3% on Friday after its quarterly results showed higher Dupixent profits and the removal of a development repayment that had reduced revenue from its Sanofi collaboration.

The distinction matters: Regeneron benefited from both rising drug demand and a change in how much collaboration income it retained. The latter lifted the earnings base even before considering further sales growth.

Dupixent profits lifted Regeneron earnings

Sanofi records Dupixent sales, while Regeneron recognises its share of collaboration profits. Regeneron's release said higher Dupixent sales increased those profits. It also said the Sanofi Development Balance had been fully repaid before the quarter began, removing a deduction from collaboration revenue.

That supports a more specific explanation than a broad claim that drug sales were strong. Regeneron retained more of the collaboration's earnings once the repayment ended. This can support the level of future earnings, although the initial growth benefit cannot recur indefinitely.

Revenue reached $5.1 billion, up 36.3% from a year earlier and up 19.2% from the preceding quarter. Operating income rose 99.5%, substantially faster than revenue.

The release also reported record sales for EYLEA HD and Libtayo. Yet EYLEA HD's growth did not fully offset declining sales of the older EYLEA product across their combined US business. Regeneron attributed the older drug's decline to competitive pressure and patients moving to EYLEA HD.

The share-price response was unusually large: 6.3x the typical daily move of 2.1%, and the largest rise since 8 September 2022. Trading volume was 3.9x its recent average. The S&P proxy fell 1.8%, while the median covered biotechnology peer fell 2.5%, reinforcing the company-specific explanation.

Cash generation tempers the earnings improvement

The strongest alternative interpretation is that the quarter demonstrates an improved collaboration income base more clearly than a sustained acceleration across the whole business.

Quarterly free cash flow reached $1.5 billion, compared with $1.4 billion a year earlier. That improvement was much less pronounced than the operating-profit increase. Across the trailing annual period, free cash flow fell 9.4%, while capital expenditure rose 20.1%.

Those figures do not negate the Dupixent improvement. They show why stronger accounting earnings alone cannot establish that cash available after investment is growing at the same pace. The Regeneron company analysis provides the wider financial history.

Growth and cash margins determine model value

Cash conversion pulls in the opposite direction.

Under the stated slower-growth scenario, model value falls 22.9%. If the past year's free-cash-flow margin deterioration persists, model value falls 22.6%. The similar effects show that sustaining cash margins matters alongside maintaining sales growth.

These are model values under stated assumptions, not a comparison with the share price.

The next results will test whether higher Sanofi collaboration income continues to translate into cash, and whether EYLEA HD can stabilise the combined eye-drug business. Continued Dupixent demand with improving cash conversion would strengthen the earnings interpretation behind Friday's rise. Renewed cash weakness or deeper combined EYLEA erosion would weaken it.